Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
Delayed Quote. Delayed Nyse - 11/19 04:02:44 pm
89.02 USD   +0.33%
09:34aABBVIE : Form 8.3 - -2-
DJ
09:34aABBVIE : Form 8.3 -
DJ
11/18ALLERGAN : Form 8.3 -
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AbbVie : Gets CHMP Positive Opinion for Rinvoq in Rheumatoid Arthritis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/18/2019 | 08:08am EST

By Michael Dabaie

AbbVie Inc. (ABBV) said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Rinvoq for the treatment of adult patients with moderate to severe active rheumatoid arthritis.

The CHMP positive opinion is supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, AbbVie said. The opinion will now be referred to the European Commission for final approval, the company said.

In Phase 3 trials, upadacitinib improved signs and symptoms of rheumatoid arthritis, inhibited radiographic progression and improved physical function, AbbVie said.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
09:34aABBVIE : Form 8.3 - -2-
DJ
09:34aABBVIE : Form 8.3 -
DJ
11/18ALLERGAN : Form 8.3 -
DJ
11/18ABBVIE : Form 8.3 -
DJ
11/18ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/18ABBVIE : Announces Extension of Expiration Date for Exchange Offers for Allergan..
PR
11/18PFIZER : FDA Approves Humira Biosimilar Abrilada for Multiple Conditions
DJ
11/15ABBVIE : Form 8.3 -
DJ
11/14Rising Treasury Yields Quiet Investors' Concerns -- 2nd Update
DJ
11/14Rising Treasury Yields Quiet Investors' Concerns -- Update
DJ
More news
Financials (USD)
Sales 2019 33 293 M
EBIT 2019 15 768 M
Net income 2019 8 578 M
Debt 2019 30 704 M
Yield 2019 4,83%
P/E ratio 2019 14,9x
P/E ratio 2020 9,73x
EV / Sales2019 4,88x
EV / Sales2020 4,36x
Capitalization 132 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 94,36  $
Last Close Price 89,02  $
Spread / Highest target 46,0%
Spread / Average Target 6,00%
Spread / Lowest Target -9,01%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-3.75%131 216
JOHNSON & JOHNSON4.56%354 855
ROCHE HOLDING AG21.63%259 443
MERCK AND COMPANY10.10%214 194
PFIZER-14.73%205 980
NOVARTIS19.39%204 533